Postoperative analgesia in patients undergoing shoulder arthroscopy
Conditions
Interventions
Experimental group:PCIA formula is tagilidine (specific concentration is set according to the preliminary pre-test results and drug package insert recommendations, currently 0.5 mg/mL is tentatively p
Control group:The PCIA formulation was HYDROmorphone hydrochloride (40µg/mL), and the background infusion, booster dose and lockout time were consistent with those of the test group.
Sponsors
People's Hospital of Ningxia Hui Autonomous Region
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Age 18-65 years, ASA class I-II; 2.Elective unilateral shoulder arthroscopic rotator cuff repair or Bankart repair; 3.PCIA analgesia required after surgery; 4.Informed consent signed
Exclusion criteria
Exclusion criteria: 1. Long-term opioid use (>=4 consecutive weeks); 2. Known allergy to opioids; 3. Severe liver and kidney dysfunction; 4. Patients with acute or severe bronchial asthma; 5. Patients with known or suspected gastrointestinal obstruction; 6. High risk of obstructive sleep apnea (STOP-Bang score >=3); 7.BMI>=30 kg/m^2; 8. Pregnancy or lactation; 9. Inability to cooperate with pain assessment or follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the time-weighted curve of resting NRS score within 48 hours after surgery;Incidence of moderate to severe nausea and vomiting and respiratory depression within 48 hours after operation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Rest and passive activity NRS scores at various time points after surgery;Interleukin-6 (IL-6) and C-reactive protein (CRP) levels; | — |
Countries
China
Contacts
Public ContactZhi Yu
People's Hospital of Ningxia Hui Autonomous Region
Outcome results
None listed